The disclosure relates to a family of pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof. The compositions form a layered pellet which contain the therapeutic active compound, a rate release controlling polymer and pH responding polymer (that is ionic and non-ionic polymers) polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The core of the therapeutic active compound contains an azole (either pyrazole or imidazole), a pyridine and an alkyne group. The compositions provide a pH-independent in vitro release profile with NMT 70 % in one hour, NMT 85 % in 4 hour, and NLT 80 % in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment- Resistant Depression (TRD) and Fragile X Syndrome.
